Photodynamic therapy combined with posterior subtenon triamcinolone acetonide injection in the treatment of choroidal neovascularization

Eye

Volumn 23, Issue 3, 2009, Pages 645-651

  Lee, Y A ^a   Ho, T C ^a   Chen, M S ^a   Yang, C H ^a   Yang, C M ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Choroidal neovascularization; Photodynamic therapy; Posterior subtenon injection; Triamcinolone acetonide

Indexed keywords

TRIAMCINOLONE ACETONIDE; GLUCOCORTICOID;

ADULT; AGE DISTRIBUTION; CATARACT; CONTROLLED STUDY; ENDOPHTHALMITIS; FEMALE; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAOCULAR PRESSURE; MAJOR CLINICAL STUDY; MALE; MEMBRANE PERMEABILITY; MYOPIA; PHOTODYNAMIC THERAPY; RETINA DETACHMENT; REVIEW; SIDE EFFECT; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY; AGED; CHOROIDAL NEOVASCULARIZATION; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; EVALUATION STUDY; INTRAOCULAR DRUG ADMINISTRATION; MIDDLE AGED; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; CHOROIDAL NEOVASCULARIZATION; DRUG THERAPY, COMBINATION; FEMALE; GLUCOCORTICOIDS; HUMANS; INJECTIONS, INTRAOCULAR; MALE; MIDDLE AGED; MYOPIA; PHOTOCHEMOTHERAPY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAMCINOLONE ACETONIDE; VISUAL ACUITY;

EID: 62549162124     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2008.17     Document Type: Review

References (46)

1. Green WR, Wilson DJ. Choroidal neovascularization. Ophthalmology 1986; 93: 1169-1176.
2. Klaver CC, Wolfs RC, Vingerling JR, Hofman A, de Jong PT. Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study. Arch Ophthalmol 1998; 116: 653-658.
3. Ferris III FL, Fine SL, Hyman L. Age-related macular degeneration and blindness due to neovascular maculopathy. Arch Ophthalmol 1984; 102: 1640-1642.
4. Miller DG, Singerman LJ. Vision loss in younger patients: a review of choroidal neovascularization. Optom Vis Sci 2006; 83: 316-625.
5. Avila MP, Weiter JJ, Jalkh AE, Trempe CL, Pruett RC, Schepens CL. Natural history of choroidal neovascularization in degenerative myopia. Ophthalmology 1984; 91: 1573-1581.
6. Hampton GR, Kohen D, Bird AC. Visual prognosis of disciform degeneration in myopia. Ophthalmology 1983; 90: 923-926.
7. Wong TY, Foster PJ, Hee J, Ng TP, Tielsch JM, Chew SJ et al. Prevalence and risk factors for refractive errors in adult Chinese in Singapore. Invest Ophthalmol Vis Sci 2000; 41: 2486-2494.
8. Lin LL, Shih YF, Hsiao CK, Chen CJ. Prevalence of myopia in Taiwanese schoolchildren: 1983-2000. Ann Acad Med Singapore 2004; 33: 27-33.
9. Bressler NM, Arnold J, Benchaboune M, Blumenkranz MS, Fish GE, Gragoudas ES et al. Verteporfin therapy of subfoveal choroidal neovascularization in patients with age-related macular degeneration: additional information regarding baseline lesion composition's impact on vision outcomes-TAP report No. 3. Arch Ophthalmol 2002; 120: 1443-1454.
10. Verteporfin in Photodynamic Therapy Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization - verteporfin in photodynamic therapy report 2. Am J Ophthalmol 2001; 131: 541-560.
11. Verteporfin in Photodynamic Therapy Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in pathologic myopia with verteporfin. 1-year results of a randomized clinical trial - VIP report no. 1. Ophthalmology 2001; 108: 841-852.
12. Verteporfin Roundtable Participants. Guidelines for using verteporfin (Visudyne) in photodynamic therapy for choroidal neovascularization due to age-related macular degeneration and other causes: update. Retina 2005; 25: 119-134.
13. Schmidt-Erfurth U, Schlötzer-Schrehard U, Cursiefen C, Michels S, Beckendorf A, Naumann GO. Influence of photodynamic therapy on expression of vascular endothelial growth factor (VEGF), VEGF receptor 3, and pigment epithelium-derived factor. Invest Ophthalmol Vis Sci 2003; 44: 4473-4480.
14. Grossniklaus HE, Green WR. Choroidal neovascularization. Am J Ophthalmol 2004; 137: 496-503.
15. Augustin AJ, Schmidt-Erfurth U. Verteporfin therapy combined with intravitreal triamcinolone in all types of choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006; 11: 14-22.
16. Augustin AJ, Schmidt-Erfurth U. Verteporfin and intravitreal triamcinolone acetonide combination therapy for occult choroidal neovascularization in age-related macular degeneration. Am J Ophthalmol 2006; 141: 638-645.
17. Ruiz-Moreno JM, Montero JA, Barile S, Zarbin MA. Photodynamic therapy and high-dose intravitreal triamcinolone to treat exudative age-related macular degeneration: 1-year outcome. Retina 2006; 26: 602-612.
18. Arias L, Garcia-Arumi J, Ramon JM, Badia M, Rubio M, Pujol O. Photodynamic therapy with intravitreal triamcinolone in predominantly classic choroidal neovascularization: one-year results of a randomized study. Ophthalmology 2006; 113: 2243-2250.
19. Spaide RF, Sorenson J, Maranan L. Photodynamic therapy with verteporfin combined with intravitreal injection of triamcinolone acetonide for choroidal neovascularization. Ophthalmology 2005; 112: 301-304.
20. Zarbin M. Should corticosteroids be considered as part of the standard care with photodynamic therapy? Arch Ophthalmol 2006; 124: 563-571.
21. Helm CJ, Holland GN. The effects of posterior subtenon injection of triamcinolone acetonide in patients with intermediate uveitis. Am J Ophthalmol 1995; 120: 55-64.
22. Van de Moere A, Sandhu SS, Kak R, Mitchell KW, Talks SJ. Effect of posterior juxtascleral triamcinolone acetonide on choroidal neovascular growth after photodynamic therapy with verteporfin. Ophthalmology 2005; 112: 1896-1903.
23. Mueller AJ, Jian G, Banker AS, Rahhal FM, Capparelli E, Freeman WR. The effect of deep posterior subtenon injection of corticosteroids on intraocular pressure. Am J Ophthalmol 1998; 125: 158-163.
24. Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials - TAP report. Arch Ophthalmol 1999; 117: 1329-1345.
25. Bakri SJ, Kaiser PK. Posterior subtenon triamcinolone acetonide for refractory diabetic macular edema. Am J Ophthalmol 2005; 139: 290-294.
26. Neovascular Age-Related Macular Degeneration, Periocular Corticosteroids and Photodynamic Therapy (NAPP) Trial Research Group. Periocular triamcinolone and photodynamic therapy for subfoveal choroidal neovascularization in age-related macular degeneration. Ophthalmology 2007; 114: 1713-1721.
27. Ciulla TA, Criswell MH, Danis RP, Hill TE. Intravitreal triamcinolone acetonide inhibits choroidal neovascularization in a laser-treated rat model. Arch Ophthalmol 2001; 119: 399-404.
28. Ciulla TA, Criswell MH, Danis RP, Fronheiser M, Yuan P, Cox TA et al. Choroidal neovascular membrane inhibition in a laser treated rat model with intraocular sustained release triamcinolone acetonide microimplants. Br J Ophthalmol 2003; 87: 1032-1037.
29. Schmidt-Erfurth U, Michels S, Augustin A. Perspectives on verteporfin therapy combined with intravitreal corticosteroids. Arch Ophthalmol 2006; 124: 561-563.
30. Agrawal S, Agrawal J, Agrawal TP. Vitrectomy as a treatment for elevated intraocular pressure following intravitreal injection of triamcinolone acetonide. Am J Ophthalmol 2004; 138: 679-680.
31. Jonas JB, Akkoyun I, Budde WM, Kreissig I, Degenring RF. Intravitreal reinjection of triamcinolone for exudative age-related macular degeneration. Arch Ophthalmol 2004; 122: 218-222.
32. Marticorena J, Gomez-Ulla F, Fernandez M, Pazos B, Rodriguez-Cid MJ, Sanchez-Salorio M. Combined photodynamic therapy and intravitreal triamcinolone acetonide for the treatment of myopic subfoveal choroidal neovascularization. Am J Ophthalmol 2006; 142: 335-337.
33. Chan WM, Lai TY, Wong AL, Liu DT, Lam DS. Combined photodynamic therapy and intravitreal triamcinolone injection for the treatment of choroidal neovascularisation secondary to pathological myopia: a pilot study. Br J Ophthalmol 2007; 91: 174-179.
34. Kojima A, Ohno-Matsui K, Futagami S, Shimada N, Tokoro T, Mochizuki M. Trans-Tenon's retrobulbar triamcinolone infusion for myopic choroidal neovascularization. Acta Ophthalmol Scand 2006; 84: 749-754.
35. Rada JA, Shelton S, Norton TT. The sclera and myopia. Exp Eye Res 2006; 82: 185-200.
36. Ruiz-Moreno JM, Montero JA. Subretinal fibrosis after photodynamic therapy in subfoveal choroidal neovascularisation in highly myopic eyes. Br J Ophthalmol 2003; 87: 856-859.
37. 2-production by polymorphonuclear leukocytes of patients receiving corticosteroids. J Clin Lab Immunol 1990; 33: 117-123.
38. Weishaupt KR, Gomer CJ, Dougherty TJ. Identification of singlet oxygen as the cytotoxic agent in photoinactivation of a murine tumor. Cancer Res 1976; 36: 2326-2329.
39. Sutter FK, Kurz-Levin MM, Scherrer M, Barthelmes D, Fleischhauer JC, Helbig H. Intravitreal triamcinolone acetonide for serous retinal pigment epithelial detachments in exudative age-related macular degeneration. Klin Monatsbl Augenheilkd 2007; 224: 297-299.
40. Liggett PE, Colina J, Chaudhry NA, Tom D, Haffner G. Triple therapy of intravitreal triamcinolone, photodynamic therapy, and pegaptanib sodium for choroidal neovascularization. Am J Ophthalmol 2006; 142: 1072-1074.
41. Augustin AJ, Puls S, Offermann I. Triple therapy for choroidal neovascularization due to age-related macular degeneration: verteporfin PDT, bevacizumab, and dexamethasone. Retina 2007; 27: 133-140.
42. Dhalla MS, Shah GK, Blinder KJ, Ryan EH, Mittra RA, Tewari A. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for choroidal neovascularization in age-related macular degeneration. Retina 2006; 26: 988-993.
43. Rosenfeld PJ, Brown DM, Heier JS, Boyer DS, Kaiser PK, Chung CY et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006; 355: 1419-1431.
44. Narayanan R, Kuppermann BD, Jones C, Kirkpatrick P. Ranibizumab. Nat Rev Drug Discov 2006; 5: 815-816.
45. Emerson MV, Lauer AK, Flaxel CJ, Wilson DJ, Francis PJ, Stout JT et al. Intravitreal bevacizumab (Avastin) treatment of neovascular age-related macular degeneration. Retina 2007; 27: 439-444.
46. Sakaguchi H, Ikuno Y, Gomi F, Kamei M, Sawa M, Tsujikawa M et al. Intravitreal injection of bevacizumab for choroidal neovascularisation associated with pathological myopia. Br J Ophthalmol 2007; 91: 161-165.